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Abstract
Background:  Regulatory  t  cells  (treg)  and  dendritic
cells (Dc) play an important role in tumor immunity
and immune escape. However, their interplay and the
effects of anti-cancer therapy on the human immune
system are largely unknown.
Methods: For Dc generation, cD14+ monocytes were
enriched by immunomagnetic selection from peripher-
al  blood  of  advanced  head  and  neck  squamous  cell
carcinoma (Hnscc) patients and differentiated into
immature Dc using GM-scF and Il-4. Dc matura-
tion was induced by addition of tnFʱ. the frequency
of cD4+cD25highFoXP3+ treg in Hnscc patients
was  analyzed  before  and  after  radio-chemotherapy
(Rct) by four-color flow cytometry.
Results: In  Hnscc  patients,  the  frequency  of  treg
(0.33 ﾱ 0.06%) was significantly (p = 0.001) increased
compared to healthy controls (0.11 ﾱ 0.02%), whereas
Rct had variable effects on the treg frequency induc-
ing its increase in some patients and decrease in oth-
ers. after six days in culture, monocytes of all patients
had differentiated into immature Dc. However, Dc
maturation indicated by cD83 up-regulation (70.7 ﾱ
5.5%) was successful only in a subgroup of patients
and correlated well with lower frequencies of periph-
eral blood treg in those patients.
Conclusion: the frequency of regulatory t cells is ele-
vated in Hnscc patients and may be modulated by
Rct. Monocyte-derived Dc in Hnscc patients show
a  maturation  deficiency  ex  vivo.  those  preliminary
data may have an impact on multimodality clinical tri-
als integrating cellular immune modulation in patients
with advanced Hnscc.
Key words: head and neck cancer, dendritic cell, vacci-
nation, regulatory t cell, chemotherapy
Abbreviations: 
5-Fu 5-fluorouracil
Dc Dendritic cells
FoXP3 Forkhead box P3
GM-csF Granulocytemacrophagecolony-stimulating 
factor
Hnscc Head and neck squamous cell cancer
PBMc Peripheral blood mononuclear cells
Rct Radio-chemotherapy
tGFb transforming growth factor beta
tnFʱ tumor necrosis factor alpha
treg Regulatory t cells
IntRoDuctIon
Radical  surgery  and  various  radio-chemotherapy
(Rct)  regimens  represent  the  current  therapy  stan-
dards for patients with head and neck squamous cell
cancer (Hnscc). However, local recurrence and dis-
tant metastasis are still the major limiting factors for
improving  survival  rates  [1].  aside  from  anti-EGFR
antibody therapy and targeted therapy with tyrosine ki-
nase  inhibitors,  newer  therapeutic  approaches  have
been  focused  on  dendritic  cell  (Dc)-based  im-
munotherapy  [2].  Dc  are  unique  antigen-presenting
cells  characterized  by  their  potent  t-cell  stimulatory
activity and therefore, they are preferentially utilized in
cancer vaccines [3]. Immature Dc capture antigens in
peripheral tissues and migrate to secondary lymphoid
organs after danger signal-induced maturation. there,
Dc present the captured antigens to specific t cells.
For cancer vaccination, Dc are loaded with specific
tumor antigen or mRna and administered to cancer
patients in hope of stimulating an anti-tumor t-cell re-
sponse [4]. a number of human vaccination studies
utilizing Dc have been recently published for various
tumor  entities,  however,  Dc-based  vaccinations  for
therapy of human Hnscc are rare [5].
the  production  of  Dc-based  vaccines  requires
techniques for a large-scale ex vivo generation of clini-
cal-grade Dc, and several methods for Dc generation
have been established [3]. Dc can be directly isolated
from the peripheral blood, which may be hampered by
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in cancer patients [6]. currently, Dc culture for thera-
py  utilizes  monocytes  separated  from  leukapheresis
products [7]. For this purpose, in patients with cancer,
monocytes have to be collected before Rct as their
number drops rapidly after Rct. Whether Hnscc pa-
tients  at  this  disease  stage  have  functionally  normal
monocytes which can be used to generate Dc vaccines
is currently unknown.
to date, Dc-based vaccines for cancer have not yet
fulfilled  their  promise,  as  clinical  benefits  are  only
rarely reported in therapeutic vaccination trials, such
as in prostate cancer [8]. this lack of clinical benefits
might be partly due to the strong immunosuppressive
influence  of  regulatory  t  cells  (treg)  in  cancer  pa-
tients with advanced malignancies.
cD4+cD25highFoXP3+ treg play an important role
in various human diseases including the development
of allergy [9], host-versus-graft-reaction in transplan-
tation [10], and autoimmune diseases [11]. all are as-
sociated with a decrease in treg numbers. In contrast,
in cancer patients, treg are frequently elevated and can
inhibit t-cells, Dc, natural killer t-cells and even B-
cells, thereby probably contributing to tumor immune
escape [12]. the potential influence of Rct on treg
has been addressed in several recent studies. In breast
cancer, FoXP3+ cells infiltrating the tumor were de-
creased in frequency after neoadjuvant chemotherapy,
and  a  reduced  treg  infiltration  correlated  with  im-
proved  responses  [13].  also  in  breast  cancer,
trastuzumab therapy in combination with chemothera-
py resulted in a decrease of treg in peripheral blood
[14]. In end-stage cancer patients with various tumor
types, a low dose of cyclosphosphamide caused a se-
lective depletion of treg in peripheral blood [15]. For
Hnscc, a study by strauss et al. showed that onco-
logic therapy induced a significant increase in the fre-
quency and suppressor function of treg in the periph-
eral  circulation.  surprisingly,  Hnscc  patients  had  a
higher  frequency  of  treg  after  successful  therapy
compared  to  patients  with  active  untreated  disease
[16].
the present study focuses on Dc generation and
the alteration of cD4+cD25highFoXP3+ treg during
Rct in Hnscc patients. understanding the frequen-
cy and function of treg and Dc is necessary to effec-
tively  orchestrate  the  various  regimens  of  surgery,
Rct and anti-cancer immune therapy.
MatERIal anD MEtHoDs
Study design
Patients of all age groups with the diagnosis of Hn-
scc (t1-4) donated blood for the generation of Dc
(mean age: 63.1yrs, 0 female, 9 male) and treg quan-
tification (mean age: 58.8yrs, 2 female, 11 male) after
informed consent. Experiments were approved by the
local ethics committee. two patients suffered from re-
current tumor disease, and all patients received prima-
ry or adjuvant Rct with curative intent (table 1). Dc
generation was performed prior to Rct, and the fre-
quency of treg was determined before as well as one
week (6.8 ﾱ 2 days) after chemotherapy. three differ-
ent protocols of chemotherapy were distinguished: (a)
single dose of cisplatin (n = 3), (b) one course of 5-
fluorouracil and cisplatin ﾱ cetuximab (n = 4), and (c)
one course of mitomycin c and cisplatin (n = 6). the
control group consisted of 10 healthy volunteers.
Generation of  dendritic cells
Dc were generated following a protocol adapted from
Zhou  et  al.  [17,  18].  cD14+ monocytes  were  im-
munoselected  from  peripheral  blood  mononuclear
cells (PBMc) using ls separation columns on a Vari-
oMacs  (Miltenyi  Biotec,  Bergisch  Gladbach,  Ger-
many). Enriched cD14+ monocytes were cultured in
24-well  plates  (Greiner,  n￼rtingen,  Germany)  at
1x10 6 cells/ml  and  2ml/well  of  serum-free  cell-
GroDc medium (cellgenix, Freiburg, Germany) sup-
plemented  with  1,000  u/ml  GM-csF  (leukine,
Berlex, Richmond, ca) and 1,000 u/ml Il-4 (cell-
genix). after 3 and 6 days, half of the medium was re-
placed by fresh medium containing cytokines. to in-
duce Dc maturation, 1,000 u/ml tnFʱ (cellgenix),
GM-csF and Il-4 were added on day 6, and cultures
were continued for 3 days. Monocyte purity was deter-
mined  by  flow  cytometry,  using  cD45-FItc  (BD 
Biosciences,  Heidelberg,  Germany)  and  cD14-PE 
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Table 1. Patients characteristics.
Dendritic cell culture Treg frequency
number and gender 9 (9 male, 0 female) 13 (11 male, 2 female)
Mean age (range) 63.1 yrs (47 – 72) 58.8 yrs (47 – 73)
tumor site: larynx 23
oral cavity 36
Pharynx 34
Maxillary sinus 10
tumor stage: t1 11
t2 12
t3 43
t4 36
Recurrent disease 02
surgical treatment 23
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antibodies. to monitor Dc differentiation and matura-
tion,  the  frequencies  of  cD14+cD83neg monocytes,
cD14negcD83neg immature Dc and cD14negcD83+
mature Dc were determined by flow cytometry using
cD14-PE and cD83-FItc (Beckman-coulter) mono-
clonal antibodies.
Flow cytometric determination of  Treg frequencies
Venous  blood  (1ml)  was  collected  in  heparinized
tubes and erythrocyte lysis was performed with 14ml
ammonium  chloride  solution  (nH4cl)  for  10min  at
4ﾰc.  after  washing  cells  twice  with  PBs,  cells  were
permeabilized  with  1ml  cytofix  solution  (BD  Bio-
sciences)  for  15min  at  4ﾰc,  washed  twice  with
Permwash  solution  (BD  Biosciences)  and  stained  in
Permwash solution with cD25-PEcy5, cD4-PEcy7,
cD8-aPc  (all  BD  Biosciences)  and  FoXP3-FItc
(eBioscience,  Frankfurt,  Germany)  monoclonal  anti-
bodies for 20min at 4ﾰc. Finally, cells were washed in
4ml PBs and fixed with 100 ﾵl 4% para-formalde-
hyde (EMs, Hatfield, Pa) prior to analysis on a Facs
canto flow cytometer using DIVa software (BD Bio-
sciences).  treg  were  identified  as  cD4+cD25high-
FoXP3+ lymphocytes  by  sequential  gating  (Fig.  1),
and frequencies of treg are shown as percent (%) of
cD4+ lymphocytes. absolute numbers were calculated
from  frequencies  and  cell  counts  determined  on  a
blood cell analyzer.
Statistical analysis
Data are presented as geometric means ﾱ standard er-
ror of means, and statistical significance was evaluated
using the student’s t-test.
REsults
Frequency of  regulatory T cells
the frequency of treg in Hnscc patients prior and
after  radio-chemotherapy  as  well  as  in  the  control
group was determined by flow cytometry. treg were
identified  as  cD4+cD25highFoxP3+ cells  within  the
lymphocyte population (Fig. 1). the mean frequency
of cD4+cD25highFoXP3+ treg measured by flow cy-
tometry  (n  =  13)  was  significantly  increased  (p  =
0.001) in Hnscc patients prior to Rct (0.33 ﾱ 0.6%)
compared to healthy controls (0.11 ﾱ 0.2%). Rct had
diverse effects with an average treg frequency of 0.36
ﾱ 0.09% after Rct (Fig. 2). seven patients showed an
average increase of +0.28 ﾱ 0.1% in treg frequency
after Rct while the other six patients showed an aver-
age decrease of -0.21 ﾱ 0.1%.
the frequency of treg was further determined in
subgroups of patients according to their chemothera-
py protocol. Whether patients were treated with cis-
platin (n = 3), 5-fluorouracil and cisplatin ﾱ cetuximab
(n = 4), or mitomycin c and cisplatin (n = 6), no uni-
form alteration of treg frequencies was observed in
any of these subgroups (Fig. 3). We also determined
the absolute numbers of lymphocytes, treg and cD4+
t cells before and after Rct as significant variations
in Hnscc patients have been reported [19]. In Hn-
scc patients, the absolute number of treg decreased
from 11.6 ﾱ 3/ʼl before Rct to 7.1 ﾱ 3/ʼl after
Rct. correspondingly, the absolute number of cD4+
t cells in Hnscc patients decreased from 3,437 ﾱ
364/ʼl before Rct to 1,960 ﾱ 367/ʼl after Rct.
the mean number of leukocytes measured by whole
blood  count  was  8,800  ﾱ  0.7/ﾵl  before  Rct  and
5,600 ﾱ 0.6/ﾵl after Rct.
Dendritic cell generation
to analyze the functionality of monocytes in Hnscc
patients, peripheral blood monocytes were differenti-
ated into immature Dc in the presence of GM-csF
and Il-4 before maturation was induced by the addi-
tion of tnFʱ. Differentiation and maturation were
monitored  by  determining  the  expression  of  the
monocyte  marker  cD14  and  the  marker  for  mature
Dc, cD83, on the cell surface [20]. Immunomagnetic
monocyte enrichment (n = 9) resulted in a high purity
of  cD14+ cells  (85.3  ﾱ  3.2%).  after  six  days  of
monocyte  culture  with  GM-csF  and  Il-4,  cells
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Fig.  1. strategy for flow cytometric determination of treg
frequencies. treg frequencies in peripheral blood of patients
and controls were determined by flow cytometry. lympho-
cytes (a) were identified based on their forward (Fsc) and
side scatter characteristic (ssc). Within the lymphocyte popu-
lation, cD4+cD8neg cells were gated (B) and the subpopula-
tion  of  cD25highFoXP3+ cells  quantitated  in  a  dotplot
showing cD25 versus FoXP3 expression (c).
3) Schuler_Umbruchvorlage  14.02.11  14:23  Seite 59showed a loss of cD14 marker (16.3 ﾱ 9.0%). cD83
expression, was detectable only on a small fraction of
cells (1.5 ﾱ 0.4%), which confirms that the cultured
monocytes had acquired the cD14negcD83neg pheno-
type of immature Dc (Fig. 4).
Following  maturation  of  the  cells  with  tnFʱ,
cD14  expression  was  almost  absent  (0.8  ﾱ  0.2%),
whereas  cD83  was  up-regulated  (38.8  ﾱ  10.6%
cD83+ cells), indicating maturation of Dc. However,
the ability of Dc to mature in Hnscc patients (n=6)
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Fig.  2.  treg frequencies in peripheral blood of
Hnscc  patients.  treg  frequencies  of  Hnscc
patients  before  and  after  Rct  (n=13)  or  from
healthy individuals (n = 10) were determined as
illustrated in Figure 1. Results are shown as per-
centages  of  cD4+cD25highFoXP3+ treg  of
cD4+ lymphocytes and displayed in quartiles of
0, 25, 75 and 100. Horizontal bars indicate geo-
metric mean values.
Fig. 3. the frequency of treg before
and after radio-chemo  therapy in indi-
vidual Hnscc patients. treg frequen-
cies before (black bars) and after ra-
dio-chemotherapy (grey bars) of indi-
vidual  patients  receiving  three  differ-
ent  Rct  regimens  were  determined.
the  mean  frequency  of  treg  in  the
control group is shown in the last col-
umn. Patients showing an increase in
treg frequency after Rct are indicat-
ed (*).
Fig. 4. successive generation of immature and mature dendritic cells from monocytes. Monocytes (day 0) were cultured for 6
days in the presence of GM-csF and Il-4 to induce Dc differentiation, followed by a three day culture period in the presence
of GM-csF, Il-4 and tnFʱ to induce Dc maturation. Monocyte purity was determined by cD45/cD14 staining (day 0). the
frequency of cD14negcD83neg immature Dc, and cD14negcD83+ mature Dc was determined after 6 and 9 days of culture by
flow cytometry. Quadrants were set according to isotype controls.
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cD4+cD25highFoXP3+ treg  before  Rct,  with  a
trend towards significance (Fig. 5). Patients with a treg
frequency below 0.4% of cD4+ t cells in the periph-
eral blood showed an increased ability of Dc matura-
tion  measured  by  cD83  expression  (70.3  ﾱ  5.5%)
compared  to  patients  with  a  treg  frequency  above
0.4% of cD4+ t cells, in which cells maintained an
immature phenotype. (20.8 ﾱ 10.5% cD83+ cells).
DIscussIon
tumor induced immunosuppression is a well known
phenomenon in cancer patients, for which changes in
the treg compartment may play a central role [21]. In
the  present  study,  it  was  documented,  that  the  fre-
quency of cD4+cD25highFoXP3+ treg in peripheral
blood of Hnscc patients was significantly increased
compared  to  healthy  controls,  suggesting  an  active
mechanism  of  tumor-induced  immune  escape.  this
finding is in accordance with a previous study in Hn-
scc [16] and similar changes have also been reported
for other types of cancer [12].
Rct  has  been  reported  to  preferentially  deplete
cD4+ t cells in Hnscc patients [19]. analyzing the
effects of Rct on the treg population, we observed
that in 7/13 patients treg frequencies within cD4+ t
cells  increased,  whereas  6/13  patients  showed  a  de-
crease in treg frequencies after Rct. Presumably, not
all chemotherapeutic agents have the same effect on
treg frequency, and t cell subsets may be affected dif-
ferently by Rct [22]. studies with a higher number of
patients receiving the same drug regimen could pro-
vide a more definite result. of note, a lack of a dis-
tinct phenotypic marker for human treg makes com-
parison  of  data  obtained  by  different  investigators 
difficult.  Most  commonly,  treg  are  defined  as
cD4+cD25highFoXP3+,  but  also  the  presence  of
cD39,  and the absence of cD127 and cD49d have
been used to define treg [23].
the results presented here suggest that there might
be an association between the treg frequency and ab-
normalities  in  Dc  maturation.  In  Hnscc  patients
with  a  high  frequency  of  treg  in  peripheral  blood,
monocytes failed to develop to mature Dc ex vivo as
evident by the lack of cD83 up-regulation. Hnscc
patients with a low frequency of treg show a normal
ability  of  Dc  maturation  as  compared  to  normal
donors who had 65 ﾱ 6.8% cD83+ cells after tnFʱ -
induced Dc maturation [18]. Whether such effects are
long lasting or whether there is normalization when
treg are depleted, is currently unknown.
the  defective  Dc  maturation  of  monocytes  ob-
tained from cancer patients possibly reflects tumor-in-
duced suppression, and tnFʱ used as the only matu-
ration signal may not be sufficient to overcome this
suppression. several factors that negatively influence
Dc maturation in vitro are described in the literature
including Il-10 and tGF￟ production by regulatory t
cells  [24]  or  vascular  endothelial  growth  factor  pro-
duced by human cancer cells [25]. Both mechanisms, a
direct effect mediated by tumor cells or a tumor-in-
duced  effect  mediated  by  treg,  could  cause  the  de-
creased Dc maturation in Hnscc patients. In anoth-
er study, high thrombocyte counts in blood samples
were  found  to  interfere  with  Dc  development  [26],
but  thrombocyte  counts  were  in  a  normal  range  in 
all participants of this study (data not shown). also,
neither the patients’ age nor their level of alcohol and
nicotine  consumption  gave  an  explanation  for  the 
deficiency in Dc maturation of certain patients (data
not  shown).  nevertheless,  it  should  be  stressed, 
that monocytes of all patients differentiated normally
to  immature  Dc  upon  culture  with  GM-csF  and 
Il-4,  thus,  only  maturation  of  Dc  appears  to  be 
affected.
aiming for an increase in survival rates, future ther-
apy of Hnscc patients will likely focus on the com-
bination of surgery, Rct and immunotherapy. In or-
der to determine an optimal and feasible timing of the
various  therapeutic  modalities,  the  understanding  of
depletion and recovery of immuno-relevant cell popu-
lations is essential. therefore, longitudinal studies of
cell frequencies, including treg but also myeloid sup-
pressor  cells  and  tH-17  cells  are  warranted,  all  of
which may be differently affected by Rct. Having in
mind that treg are highly immunosuppressive, the ap-
plication  of  Dc-based  anticancer  vaccination  would
be most effective when frequencies of treg are low
and those of cD4+ and cD8+ lymphocytes are com-
paratively  high.  Whether  this  point  of  time  can  be
reached before, during or after Rct needs to be deter-
mined. It will also be important to identify regimens
of Rct that are most effective for elimination of im-
munosuppressive  treg  and  functional  normalization
of Dc, as well as subgroups of patients who will espe-
cially benefit from a supportive anticancer vaccination
therapy.  as  the  combination  of  Rct  and  im-
munotherapy is hypothesized to have an additive ef-
fect in cancer patients, this strategy may provide for
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Fig. 5. association of Dc maturation and treg frequency in
the peripheral blood of Hnscc patients. the frequency of
mature Dc (cD14negcD83+) after 9 days of differentiation
and  maturation  culture  is  plotted  against  the  frequency  of
cD4+cD25highFoXP3+ treg in the blood of Hnscc pa-
tients prior to Rct (n = 6). treg frequencies are shown as
percent (%) of cD4+ lymphocytes.
3) Schuler_Umbruchvorlage  14.02.11  14:23  Seite 61the opportunity to employ Rct in a more concerted
manner [27, 28].
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